Company intelligence / Profile preview
Research Genetic Cancer Centre Group
Zug, Switzerlandrgcc-international.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SOT therapy, based on siRNA-guided gene silencing and tailored to each patient's circulating tumor cell genomic profile, showed positive preliminary evaluations in roughly 78% of cancer patients, with KI (Karnofsky-Index) improvement in 72% of cases; aCGH platform exhibits high sensitivity/specificity for cancer of unknown primary
- Therapeutic areas
- Oncology
- Modalities
- Antisense oligonucleotideSmall interfering RNALiquid biopsyGenomic profiling
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Research Genetic Cancer Centre Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Research Genetic Cancer Centre Group.